摘要
目的:探析微柱凝胶技术(MCGT)在ABO新生儿溶血病输血治疗前检测中的临床价值。方法:将本院2019年1月~2020年1月收治的30例ABO新生儿溶血病患儿纳入研究中,均采集血标本,并制放散液标本,随机选取ABO同型红细胞制剂(5份),开展交叉配血,进行凝聚胺技术(MPT)和微柱凝胶技术(MCGT)检验,对比测定结果。结果:本组患儿血清交叉配血共150次,血清、放散液MCGT检测不合格率低于血清、放散液MPT检测不合格率,差异有统计学意义(P<0.05);MPT、MCGT在血清和放散液交叉配血检测中一致性不具有统计学意义(P>0.05),MCGT检测灵敏度较低。结论:在ABO新生儿溶血病输血治疗前MCGT新生儿交叉配血检验,需要辅助直接抗人球蛋白试验,有一定临床使用价值。
Objective:To explore the clinical value of microcolumn gel technology(MCGT)in the detection of hemolytic disease of newborn ABO before blood transfusion.Methods:30 cases of ABO hemolytic disease of newborn in our hospital from January 2019 to January 2020 were included in the study.Blood samples were collected and liquid samples were distributed.At the same time,5 ABO identical red blood cell preparations were randomly selected for cross matching,and the results were compared with polyglutamine technique(MPT)and microcolumn gel technology(MCGT).Results:There were 150 times of serum cross matching in this group of children.The unqualified rate of MCGT in serum and effusion was lower than that in MPT test of serum and exudate,and the difference was statistically significant(P<0.05);the consistency of MPT and MCGT in serum and exsanguine cross matching detection was not statistically significant(P>0.05),and the detection sensitivity of MCGT was low.Conclusion:In ABO hemolytic disease before blood transfusion treatment,MCGT neonatal cross matching test,need to assist direct anti human globulin test,has a certain clinical value.
作者
陈大勇
CHEN Da-yong(Blood Transfusion Department,Shaowu Municipal Hospital,Fujian Shaowu 354000)
出处
《中国医疗器械信息》
2020年第22期14-16,共3页
China Medical Device Information
关键词
微柱凝胶
ABO血型
新生儿溶血病
输血
microcolumn gel
ABO blood group
hemolytic disease of newborn
blood transfusion
